Hypothalamic releasing hormone
Thyrotropin-Releasing Hormone (TRH)
TRH's half-life in people was 4.0 minutes (alpha phase) and 20.4 minutes (beta phase) after an intravenous dose; the app lists 0.08 hours, about 4.8 minutes.1
Thyrotropin-Releasing Hormone (TRH) after one dose: 50% at ~0.08 h, 25% at 0.16 h, 12.5% at 0.24 h.
Drawn from the half-life in the app's model, ~0.08 h. The model's figures
- Compound
- Thyrotropin-Releasing Hormone (TRH)
- Symbol
- TRH
- Family
- Metabolic and mitochondrial peptides
- Parts
- 13
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
TRH, generic name protirelin, is a hypothalamic tripeptide that the app describes as pGlu-His-Pro-NH2 (pyroglutamyl-histidyl-proline amide). Szuba and colleagues (University of Pennsylvania, Journal of Clinical Psychopharmacology, 2005) describe it as "a tripeptide that produces endocrine and behavioral effects in animals and humans".2 The American Thyroid Association reported on 24 July 2002 that production of Thyrel TRH (protirelin) "has been halted as of July 2002", and that "Since the development of ultrasensitive TSH assays, the indications for use of TRH for thyroid axis testing have become fairly limited".3 The Drugs.com consumer drug information for Thyrel TRH states that "Protirelin is used to test the response of the anterior pituitary gland in people who may have certain medical conditions involving the thyroid gland" and that the drug "has been discontinued in the United States".4 The app grades the evidence for TRH as moderate and notes that evidence for human enhancement uses is thin and confounded. The human trials described below enrolled people with depression or amyotrophic lateral sclerosis (ALS), and no controlled trial in healthy volunteers was identified in the PubMed records returned for queries on TRH with depression and with ALS.
How it works
Gershengorn and Osman (Cornell University Medical College, Physiological Reviews, 1996) write that TRH receptor complementary DNAs "have been cloned from several species" and that the deduced amino acid sequences "are compatible with TRH-R being a seven-transmembrane-spanning G protein-coupled receptor".5 In the pituitary, the Drugs.com information says "Protirelin stimulates release of a hormone called thyroid-stimulating hormone or TSH from the anterior pituitary gland".4 In people with amyotrophic lateral sclerosis, Kaplan and colleagues found that both TSH and prolactin (PRL) responses to a standard intravenous TRH test were "blunted, but not abolished" during continuous TRH treatment.9 Itil and colleagues (Diseases of the Nervous System, 1975) reported that in depressed patients the computer EEG profiles of oral and intravenous TRH "resemble the CEEG profiles of psychostimulant compounds".6 Munsat and colleagues write that "TRH crosses the blood-brain barrier poorly, if at all", the reasoning behind their intrathecal trial in ALS.7 Brooks and colleagues (William S. Middleton Memorial Veterans Administration Hospital, Neurological Research, 1988) reported that in ALS patients "TRH entry into the CSF is comparable following subcutaneous or intravenous administration".8 The mood and arousal effects reported in people are therefore descriptions of what happened after dosing in the trials below; the sources read do not establish which of the endocrine or central actions underlies them.
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~0.08 h
- Bioavailability
- 90%
- Typical dose
- 200–500 mcg
- Route
- SubQ
- Time to peak
- ~0.1 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~0.08 h (about 4.8 minutes) | Intravenous dose in people: half-life of 4.0 minutes in the alpha phase and 20.4 minutes (0.34 h) in the beta phase, two-compartment model, 730 microgram dose as printed in the record1; mean elimination half-life in cerebrospinal fluid of 0.90 hours after intrathecal infusion in ALS patients10 |
| Bioavailability | 90% (route SubQ) | 2.0% on average in people after oral TRH tartrate tablets taken two hours after a meal, a different route from the app's; no subcutaneous bioavailability figure in the sources read1 |
| Time to peak | ~0.1 h (about 6 minutes) | No time to peak is given in the sources read; Brooks and colleagues sampled serum at 10, 20, 40, 60 and 120 minutes during intravenous infusions and reported the subcutaneous level at 60 minutes8 |
The app's 0.08 h is about 4.8 minutes, close to the 4.0-minute alpha phase and shorter than the 20.4-minute beta phase reported by Yokohama and colleagues (Journal of Pharmacobio-Dynamics, 1984) for people.1
Brooks and colleagues gave intravenous TRH to 6 ALS patients, and serum TRH "rose from 0.03 +/- 0.02 (SD) to 17 +/- 2 ng/ml by 60 min and remained constant to 120 min".8 After subcutaneous doses in 4 and 5 patients, mean serum TRH reached 1.4 +/- 0.6 ng/ml (2.5 mg/kg) and 3.2 +/- 1.1 ng/ml (5.0 mg/kg) by 60 min; the PubMed record prints the doses in mg/kg, and the intravenous and subcutaneous doses differed, so the figures are not a bioavailability estimate.8
Munsat and colleagues (Neurology, 1987) reported that during a 2-hour intrathecal infusion "2.75% crossed the CSF/blood-brain barrier", and that infusion for 12 months at 3 mg/24 hr in three patients gave mean CSF steady-state levels of 2.88, 2.42 and 2.74 micrograms/ml.10 None of these sources reports measured TRH levels across a repeated dosing interval, so no level chart is drawn.
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Szuba and colleagues, Journal of Clinical Psychopharmacology 20052 | Randomized, double-blind, saline-controlled | 20 patients with a bipolar I or II major depressive episode (10 per group) | Intravenous TRH 500 microg or saline at midnight, assessed over 48 hours | 60% of the TRH group and 10% of the saline group had a 50% or greater fall in HAM-D within 24 hours (P = 0.03); HAM-D fell by an average of 52% against 12% (P = 0.038); modest rise in Young Mania Rating scores with TRH; no manic or hypomanic episodes |
| Callahan and colleagues, Biological Psychiatry 199711 | Double-blind comparison of intrathecal and intravenous TRH, then open trials | 2 treatment-refractory patients with bipolar II disorder | Both routes; doses not stated in the record read | Each had a robust antidepressant response by both routes; later open intravenous trials were effective until apparent tolerance developed; intrathecal TRH again produced robust responses; the authors call these "preliminary data" |
| Itil and colleagues, Diseases of the Nervous System 19756 | Controlled clinical trial of oral and intravenous TRH (per the record's publication type) | Depressed patients, number not stated in the record read | Oral and intravenous TRH; doses not stated in the record read | Similar computer EEG profiles for both forms; antidepressive effects "were not present in every patient" and effects on depressed mood were not "too impressive"; behavioral effects were seen in almost all patients, with increased interest, desire and drive for work, food and sex reported as one of the most striking findings, particularly after intravenous TRH |
| Benkert and Lücke, Arzneimittel-Forschung 197612 | Double-blind, placebo-controlled add-on to imipramine | 20 female and 10 male patients with a retarded-depressive syndrome | Imipramine 3 x 50 mg/day for 20 days; oral TRH 2 x 40 mg/day or placebo added for the first 2 weeks | No difference between the imipramine/TRH and imipramine/placebo groups on the Hamilton and self-rating scales |
| Mitsumoto and colleagues, Neurology 198613 | Double-blind crossover trials, acute intravenous and chronic subcutaneous | ALS patients: 16 in the acute trial, 25 in the chronic trial | Intravenous TRH 500 "mg" with norepinephrine or placebo at 1-week intervals; subcutaneous 25 "mg" daily for 3 months (units as printed in the record) | Statistical analysis showed no beneficial effects from either trial; CSF TRH rose 29-fold after a single injection; with daily TRH, 10 patients noted subjective improvement without objective evidence and 10 complained of worsening of the disease with objective decline after TRH was stopped |
| Munsat and colleagues, Neurology 19927 | Blinded, placebo-controlled crossover with an implanted constant-infusion pump | 36 ALS patients | Intrathecal TRH for 6 months and saline placebo for 6 months | No alteration of the progressive course; the pump system "proved to be safe, reliable, and well tolerated" |
| Kaplan and colleagues, Journal of Clinical Endocrinology and Metabolism 19869 | Pilot therapeutic trial with a comparison group on bolus doses | 4 ALS patients on continuous infusion (3 intrathecal, 1 epidural) and 4 on twice-weekly intrathecal boluses | Continuous infusion for 4 to 7 months | TSH rose by an average of 120% and T4 by 49%; no significant change in TSH, T4 or T3 in the bolus group |
Deeper analysis: Szuba and colleagues, nocturnal TRH in bipolar depression
Szuba and colleagues, from the Depression Research Unit of the University of Pennsylvania, tested the hypothesis that "nocturnal administration of TRH, when the circadian sensitivity of the TRH receptor is at its peak, may result in a more robust antidepressant effect".2 The design was randomized and double-blind: 20 patients with a bipolar I or II major depressive episode received intravenous TRH 500 microg (n = 10) or saline (n = 10) at midnight.2 The measures were the Hamilton Depression Rating (HAM-D), Young Mania Rating (YMR) and Profile of Mood scales over 48 hours, with TSH, total T4 and free T3 measured before and after dosing.2 The HAM-D results were a 50% or greater reduction within 24 hours in 60% of the TRH group against 10% of the saline group (P = 0.03), and an average HAM-D fall of 52% against 12% (P = 0.038).2 Other findings were that YMR scores showed "a modest increase" with TRH compared with saline, no manic or hypomanic episodes were observed, and the antidepressant effects "lasted up to 48 hours".2 There was "no correlation between DeltaTSH, DeltaT4, or DeltaT3 measures after TRH (or saline) administration and the change in HAM-D scores".2 The authors conclude that "Nocturnal TRH administration may produce a rapid antidepressant effect in some patients with BP I and BP II MDE".2 The PubMed record lists the grant NCRR NIH HHS M01 RR 00040 and the publication types Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; and Research Support, U.S. Gov't, P.H.S., without naming the source of the non-U.S. government support; it is a summary record, so the authors' disclosure statements, discontinuations and stated limitations are not in it and none are reported here.2 The trial enrolled 10 patients per group and assessed them over a 48-hour period after a dose at midnight.2
Deeper analysis: Munsat and colleagues, intrathecal TRH in ALS
Munsat and colleagues (Tufts University, Neurology, 1992) wrote that "Evidence that thyrotropin-releasing hormone (TRH) has prominent trophic effects on the motor system led to several negative therapeutic trials in amyotrophic lateral sclerosis".7 They reasoned that parenteral dosing might have given too little drug at the receptor, so they ran "a blinded, placebo-controlled, crossover study of intrathecal TRH in 36 patients" with an implanted constant-infusion pump, aiming for a steady-state CSF level "comparable with that shown to be effective in tissue culture experiments".7 Motor unit loss was measured with a quantitative technique, and "we did not observe any alteration of the progressive course during 6 months on TRH and 6 months on saline placebo".7 The record states that the pump system "proved to be safe, reliable, and well tolerated", and it reports no adverse event counts, deaths or discontinuations.7 The PubMed record lists the grants PHS HHS R01N24623 and NCRR NIH HHS RR-00054 and the publication types Research Support, Non-U.S. Gov't and Research Support, U.S. Gov't, P.H.S.; it does not name the source of the non-U.S. government support.7 The record does not include the authors' discussion of limitations, so none are reported here.7 The earlier controlled trial by Mitsumoto and colleagues (Neurology, 1986) also found "no beneficial effects" from acute intravenous or chronic subcutaneous TRH in ALS.13
Deeper analysis: Kaplan and colleagues, thyroid axis during continuous TRH
Kaplan and colleagues reported a pilot trial of four ALS patients given continuous TRH (three intrathecally, one epidurally), with serum TSH rising by an average of 120% and T4 by 49%, increases that were "statistically significant for all but serum T3".9 The rises persisted for the 4 to 7 months of treatment, and after withdrawal "serum TSH fell transiently below the normal range".9 Basal prolactin "was occasionally elevated in the two women" on continuous treatment, normal in the men, and growth hormone was normal in all patients.9 End-organ markers were "inconclusive": none had a rise in serum ferritin, one of four had a rise in sex hormone-binding globulin, and three had increased creatinuria.9 The authors conclude that the data "appears to raise the set-point of the pituitary-thyroid axis" and that "the metabolic consequences of these changes are uncertain".9 The trial had four patients per group; the comparison group was treated by twice weekly intrathecal bolus doses of TRH and the record describes no placebo group. The record lists the grants NIADDK NIH HHS R01-AM-35141 and NCRR NIH HHS RR-00054 and the publication type Research Support, Non-U.S. Gov't without naming that source, and gives no sponsor tie or limitations section.9
Doses reported in studies and on labels
The app lists a typical dose of 200 to 500 mcg by the subcutaneous route; this is the app's own figure. Among the sources read, the 500 mcg figure matches an intravenous dose, and none reports a subcutaneous dose of 200 to 500 mcg.4,2
| Setting and reference | Route and dose | Length | Note |
|---|---|---|---|
| Diagnostic pituitary test, Drugs.com consumer information4 | Intravenous; adults "usually given 500 micrograms (mcg)" | Length not stated | Doses differ between patients, and the dose for children is based on body weight |
| Bipolar depression, Szuba 20052 | Intravenous, 500 microg at midnight | Assessed over 48 hours | n = 10 on TRH, n = 10 on saline |
| Depression with imipramine, Benkert 197612 | Oral, 2 x 40 mg/day, against placebo | First 2 weeks of a 20-day imipramine course | 30 patients in total; no group difference |
| ALS, acute, Mitsumoto 198613 | Intravenous, "500 mg" as printed, with norepinephrine or placebo | Weekly crossover | 16 patients |
| ALS, chronic, Mitsumoto 198613 | Subcutaneous, "25 mg" as printed, daily, against saline | 3 months | 25 patients |
| ALS, intrathecal infusion, Munsat 198710 | Implanted pump, 3 mg/24 hr | 12 months | 3 patients; mean CSF steady state 2.88, 2.42 and 2.74 micrograms/ml |
| Pharmacokinetics, oral and intravenous, Yokohama 19841 | Intravenous 730 microgram; oral TRH tartrate tablets, 11.7 mg (equivalent to 8 mg of TRH) | Length not stated | Oral absolute bioavailability 2.0% on average, tablets given two hours after a meal; TSH significantly increased after oral tablets |
Side effects reported
The Drugs.com consumer information for the intravenous diagnostic test lists effects by frequency, and the sources below are in patient groups with different conditions.4
- More common in that list: flushing or redness of skin, frequent urge to urinate, headache (sometimes severe), lightheadedness, nausea, stomach pain, and an unpleasant taste in the mouth or dryness of the mouth.4
- Less common: anxiety, drowsiness, pressure in the chest or tightness in the throat, sweating and tingling.4
- Rare: fainting, and, for patients with pituitary tumors, temporary loss of vision.4
- For patients with heart or blood vessel disease, high blood pressure or a history of stroke, the information states "Sudden changes in blood pressure caused by protirelin may put patients with these conditions at greater risk".4
- In the Mitsumoto trial of subcutaneous TRH in ALS, "mild transient side effects occurred", and clinical side effects appeared with the intravenous doses.13
- In the Szuba trial, YMR scores rose modestly with TRH and no manic or hypomanic episodes were observed.2
- Callahan and colleagues describe "apparent tolerance" to repeated intravenous TRH in 2 patients with bipolar II disorder.11
Bloodwork and markers
The app lists TSH, prolactin and T4 as markers to monitor. The Drugs.com information describes the diagnostic logic: "By measuring the amount of TSH in the blood after protirelin is given, the doctor can determine how well the anterior pituitary is working".4 The American Thyroid Association says the test "can sometimes be useful in special clinical situations, such as distinguishing TSH-secreting pituitary tumors from other forms of inappropriate TSH secretion and in subtle cases of central hypothyroidism".3 Yokohama and colleagues reported that "thyroid stimulating hormone levels were significantly increased by oral administration of TRH-T tablets" in people.1 During continuous TRH in four ALS patients, TSH rose by an average of 120%, serum T4 by 49% and serum T3 by 49% (the T3 rise not statistically significant), while TSH and prolactin responses to a TRH test were blunted, and basal prolactin was occasionally raised in the two women.9 In the Szuba trial, TSH, total T4 and free T3 were measured before and after intravenous TRH 500 microg, and the changes did not correlate with the change in HAM-D scores.2
Regulatory and anti-doping status
The American Thyroid Association statement of 24 July 2002 says production of Thyrel TRH by Ferring Pharmaceuticals was halted while the manufacturer modified its process, and that "no replacement product is expected to be available until Thyrel® returns to the market".3 The Drugs.com page, last updated 8 June 2026, states that Thyrel TRH "has been discontinued in the United States".4 DailyMed returned three protirelin powder records (AX Pharmaceutical Corp, 2024; Suzhou Qianyuan Biotechnology Co., Ltd., 2022; Bluebay Shandong Co., Ltd., 2020), and the text of the AX Pharmaceutical Corp record holds product names and a package entry, without an indication, dose or safety statement.14 In the World Anti-Doping Agency's 2026 Prohibited List text, TRH, protirelin and thyrotropin are not named.15 The S2 class states that "The following substances, and other substances with similar chemical structure or similar biological effect(s), are prohibited", and the sources read do not say how WADA classifies TRH.15
What is not known
- The sources read give no subcutaneous pharmacokinetic study in people that reports bioavailability or time to peak, so the app's 90% and 0.1 h have no matching figure in the sources read.1
- The trials of mood effects enrolled patients with depression, and the sources read include no controlled trial in healthy volunteers measuring alertness or mood.2
- Szuba and colleagues' antidepressant result comes from 20 patients assessed over 48 hours after a midnight dose, and the PubMed record read for it does not report replication.2
- Itil and colleagues reported antidepressive effects that were not present in every patient, Benkert and Lücke found no difference between the imipramine/TRH and imipramine/placebo groups, and Callahan and colleagues describe apparent tolerance to repeated intravenous dosing in 2 patients.6,12,11
- The ALS trials used intravenous, subcutaneous and intrathecal routes in patients with ALS, and the sources read report no trial of these routes in people without ALS.13,7
- The consequences of long-term TRH for the thyroid axis are described in 4 patients, and Kaplan and colleagues state that the metabolic consequences "are uncertain".9
Frequently asked questions
What is the half-life of TRH?
What is the bioavailability of TRH?
Is protirelin the same as TRH?
Protirelin is the generic name for TRH in the app's entry, which also lists "thyrotropin releasing hormone" as a synonym. Thyrel TRH was the US brand name for the intravenous diagnostic product in the sources read.4
What does TRH do to TSH?
Is TRH approved by the FDA?
Is TRH banned by WADA?
Does TRH work for depression?
Did TRH work in ALS?
Guides, tools and comparisons
- Thyrotropin releasing hormone dosage chartA guide that answers a question on this compound.
- Previous in Metabolic and mitochondrial peptides: TetrathiomolybdateThe compound before this one in the class.
- Next in Metabolic and mitochondrial peptides: VasopressinThe compound after this one in the class.
References
- Yokohama S, et al. Absorption of thyrotropin-releasing hormone after oral administration of TRH tartrate monohydrate in the rat, dog and human. J Pharmacobiodyn 1984;7(2):101-11. PMID 6427443
- Szuba MP, et al. Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J Clin Psychopharmacol 2005;25(4):325-30. PMID 16012274
- American Thyroid Association. Thyrel TRH temporarily removed from market. Public health statement, 24 July 2002. American Thyroid Association statement
- Drugs.com. Thyrel TRH (intravenous): consumer drug information, last updated 8 June 2026. Drugs.com consumer information
- Gershengorn MC, Osman R. Molecular and cellular biology of thyrotropin-releasing hormone receptors. Physiol Rev 1996;76(1):175-91. PMID 8592728
- Itil TM, et al. Clinical and CNS effects of oral and I.V. thyrotropin-releasing hormone in depressed patients. Dis Nerv Syst 1975;36(9):529-36. PMID 809253
- Munsat TL, et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 1992;42(5):1049-53. PMID 1579228
- Brooks BR, et al. Thyrotropin releasing hormone uptake into serum and cerebrospinal fluid following intravenous or subcutaneous administration. Neurol Res 1988;10(4):236-8. PMID 2907112
- Kaplan MM, et al. Sustained rises in serum thyrotropin, thyroxine, and triiodothyronine during long term, continuous thyrotropin-releasing hormone treatment in patients with amyotrophic lateral sclerosis. J Clin Endocrinol Metab 1986;63(4):808-14. PMID 3091628
- Munsat TL, Taft J, Jackson IM. Pharmacokinetics of intrathecal thyrotropin-releasing hormone. Neurology 1987;37(4):597-601. PMID 3104819
- Callahan AM, et al. Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics. Biol Psychiatry 1997;41(3):264-72. PMID 9024949
- Benkert O, Lücke KH. The effect of thyrotrophin releasing hormone versus placebo in combination with basic imipramine therapy of depressive patients. Arzneimittelforschung 1976;26(6):1162-4. PMID 822857
- Mitsumoto H, et al. Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials. Neurology 1986;36(2):152-9. PMID 3080695
- AX Pharmaceutical Corp. Protirelin, DailyMed record, version 2, 17 April 2024. DailyMed record
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list